文献速递心律失常冠心病

房颤冠脉支架术后利伐沙班两种策略与剂量调整VKA的再住院比较

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
PubMed 文献 · Circulation · 2016-11-14

本研究为PIONEER AF-PCI试验的事后分析,纳入2124例接受冠脉支架的非瓣膜性房颤患者,随机分为利伐沙班15mg每日一次联合P2Y12抑制剂、利伐沙班2.5mg每日两次联合DAPT、或剂量调整VKA联合DAPT三组。结果显示两种利伐沙班方案较VKA均降低全因死亡或不良事件再住院风险。

要点

  • 利伐沙班15mg每日一次联合P2Y12抑制剂单药较VKA降低全因死亡或再住院风险(HR 0.79,P=0.008)。
  • 利伐沙班2.5mg每日两次联合DAPT较VKA降低全因死亡或再住院风险(HR 0.75,P=0.002)。
  • 出血相关和心血管相关死亡或再住院在利伐沙班方案中均降低,但其他原因再住院未减少。

核心结论

  • 在房颤接受冠脉支架患者中,利伐沙班15mg每日一次联合P2Y12抑制剂单药或2.5mg每日两次联合DAPT,较标准VKA联合DAPT降低全因死亡或不良事件再住院风险。

研究设计与样本

  • PIONEER AF-PCI试验的事后分析,纳入2124例接受支架的非瓣膜性房颤患者,随机1:1:1分为三组。
  • 组1:利伐沙班15mg每日一次联合P2Y12抑制剂12个月;组2:利伐沙班2.5mg每日两次联合DAPT(预设1、6或12个月);组3:剂量调整VKA联合DAPT。

主要发现

  • 全因死亡或不良事件再住院风险:组1为34.9%(HR 0.79,95%CI 0.66-0.94,P=0.008 vs 组3,NNT=15),组2为31.9%(HR 0.75,95%CI 0.62-0.90,P=0.002 vs 组3,NNT=10),组3为41.9%。
  • 全因死亡+潜在出血相关再住院:组1为8.6%(P=0.032 vs 组3),组2为8.0%(P=0.012 vs 组3),组3为12.4%。
  • 全因死亡+潜在心血管相关再住院:组1为21.4%(P=0.001 vs 组3),组2为21.7%(P=0.011 vs 组3),组3为29.3%。
  • 其他形式的再住院在利伐沙班方案与VKA方案间无差异。

临床怎么用

  • 对于接受冠脉支架的非瓣膜性房颤患者,可考虑利伐沙班15mg每日一次联合P2Y12抑制剂单药或利伐沙班2.5mg每日两次联合DAPT,以降低全因死亡或再住院风险。

局限性

  • 本研究为事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that a regimen of rivaroxaban plus a P2Y12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleeding and thereby have a favorable impact on all-cause mortality and the need for rehospitalization. METHODS: Stented subjects with nonvalvular atrial fibrillation (n=2124) were randomized 1:1:1 to administration of reduced-dose rivaroxaban 15 mg daily plus a P2Y12 inhibitor for 12 months (group 1); rivaroxaban 2.5 mg twice daily with stratification to a prespecified duration of DAPT of 1, 6, or 12 months (group 2); or the reference arm of dose-adjusted VKA daily with a similar DAPT stratification (group 3). The present post hoc analysis assessed the end point of all-cause mortality or recurrent hospitalization for an adverse event, which was further classified as the result of bleeding, a cardiovascular cause, or another cause blinded to treatment assignment. RESULTS: The risk of all-cause mortality or recurrent hospitalization was 34.9% in group 1 (hazard ratio=0.79; 95% confidence interval, 0.66-0.94; P=0.008 versus group 3; number needed to treat=15), 31.9% in group 2 (hazard ratio=0.75; 95% confidence interval, 0.62-0.90; P=0.002 versus group 3; number needed to treat=10), and 41.9% in group 3 (VKA+DAPT). Both all-cause death plus hospitalization potentially resulting from bleeding (group 1=8.6% [P=0.032 versus group 3], group 2=8.0% [P=0.012 versus group 3], and group 3=12.4%) and all-cause death plus rehospitalization potentially resulting from a cardiovascular cause (group 1=21.4% [P=0.001 versus group 3], group 2=21.7% [P=0.011 versus group 3], and group 3=29.3%) were reduced in the rivaroxaban arms compared with the VKA arm, but other forms of rehospitalization were not. CONCLUSIONS: Among patients with atrial fibrillation undergoing intracoronary stenting, administration of either rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy or 2.5 mg rivaroxaban twice daily plus DAPT was associated with a reduced risk of all-cause mortality or recurrent hospitalization for adverse events compared with standard-of-care VKA plus DAPT. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01830543.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gibson CM, Pinto DS, Chi G, et al. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2016. PMID: 27881555. doi:10.1161/CIRCULATIONAHA.116.025783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。